Rutra 1 Mg/ 2Mg/ 3 Mg/ 4 Mg 1 mg/ 2mg/ 3 mg/ 4 mg TABLETS
PDF Leaflet Revision Date: 26 February 2021
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of acute and chronic schizophrenia, behavioral disturbances in dementia, and conduct disorders in children.
Dosage (summary)
Adults: Start at 2 mg/day, may increase to 4-8 mg/day. Elderly: Start at 0.5 mg twice daily.
Onset of Action / Duration
Onset: 1-2 hours, Duration: 24 hours (active metabolite).
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Safety not established; may cause extrapyramidal symptoms in neonates. Avoid breastfeeding.
Key Drug Interactions
- Carbamazepine decreases plasma levels
- Fluoxetine increases plasma levels
Contraindications
- Known sensitivity to components
- Children under 5 years
- Lewy body dementia
Common side effects
- Weight gain
- Headache
- Fatigue
- Extrapyramidal symptoms
- Dizziness
Counselling Points
- Monitor for hyperglycemia
- Avoid driving until effects are known
- Caution with alcohol and CNS depressants
Serious warnings
- Tardive dyskinesia
- Neuroleptic Malignant Syndrome
- Higher mortality in elderly with dementia
Important Disclaimer
The Rutra 1 Mg/ 2Mg/ 3 Mg/ 4 Mg 1 mg/ 2mg/ 3 mg/ 4 mg TABLETS professional information leaflet below is the property of Aurogen South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
